Form 4: Atea Pharmaceuticals Director Bruce Polsky Reports Stock Transaction
SEC Form 4 Filing
Director Bruce Polsky reports a transaction involving Atea Pharmaceuticals' common stock and restricted stock units.
Summary
- On June 16, 2024, Bruce Polsky, a director of Atea Pharmaceuticals, engaged in a transaction involving the company's securities.
- Polsky acquired 33,150 shares of common stock through the conversion of restricted stock units.
- Following the transaction, Polsky directly owns 83,150 shares of Atea Pharmaceuticals' common stock.
- The restricted stock units converted on a one-for-one basis into common stock and were fully vested with no expiration date.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting a transaction by a company director. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company insiders.
Key Dates
| Date | Description |
|---|---|
| 06/16/2024 | Date of transaction involving common stock and restricted stock units. |
| 06/18/2024 | Date of signature on the SEC Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.